drugset / Trial / NCT03045341
Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment
Phase 2/3
Completed
136 enrolled
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will test the effectiveness and relative efficacy of behavioral and pharmacologic treatments, alone and in combination, for the treatment of binge eating disorder (BED) in patients with obesity. This is an acute treatment comparing behavioral weight loss alone or in combination with naltrexone/bupropion medication.
Timeline
- Start
- 2017-02-27
- Primary completion
- 2021-07-23
- Completion
- 2022-12-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bupropion | Small molecule | 360 mg | Oral |
| Subject | Naltrexone | Small molecule | 32 mg | Oral |